Us Bancorp \De\ Nektar Therapeutics Transaction History
Us Bancorp \De\
- $74.1 Billion
- Q1 2025
A detailed history of Us Bancorp \De\ transactions in Nektar Therapeutics stock. As of the latest transaction made, Us Bancorp \De\ holds 50,085 shares of NKTR stock, worth $34,558. This represents 0.0% of its overall portfolio holdings.
Number of Shares
50,085
Previous 14,000
257.75%
Holding current value
$34,558
Previous $13,000
161.54%
% of portfolio
0.0%
Previous 0.0%
Shares
27 transactions
Others Institutions Holding NKTR
# of Institutions
159Shares Held
128MCall Options Held
92.7KPut Options Held
4.9K-
Black Rock Inc. New York, NY15.2MShares$10.5 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.3MShares$8.49 Million0.0% of portfolio
-
Samlyn Capital, LLC New York, NY9.67MShares$6.67 Million0.14% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT7.81MShares$5.39 Million0.37% of portfolio
-
Acadian Asset Management LLC Boston, MA7.2MShares$4.97 Million0.02% of portfolio
About NEKTAR THERAPEUTICS
- Ticker NKTR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 187,404,992
- Market Cap $129M
- Description
- Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...